PlanTools Releases Retirement Plan Expense Benchmark Study
To fully understand whether their costs are "reasonable," plan sponsors must have reliable and accurate data upon which to base their conclusions.
High Hopes and Altered Genes
Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...
Boomers could see lower drug costs via imports
In an effort to ease prescription drug costs in the United States - especially for older Americans - four senators introduced legislation yesterday that will...
Research Total Return Leaders Based on compounded annual price appreciation and dividends for the 10-year period ending Nov. 13, 2008, for stocks trading at or above...
Stocks in health care, including biotech and pharmaceuticals, are poised for higher levels in 2008 - thanks to present valuations, developing pipelines and acquisition horizons,...
VC the Hard Way
"I spend 90 percent of my time on 5 percent of my clients' portfolios," says Dale Stevens, president of Grasswood Partners Inc., a Malibu, Calif....
A Time of Innovation
New products and other factors drive growth in health care/biotech, despite a cautious regulatory environment, analysts say. ----- Jason Kantor RBC Capital Markets 415-633-8565 Jason.email@example.com Outlook: Fundamentally, I don't think the...
Obesity: A Heavy Burden on Healthcare
Americans are growing larger and there seems to be no end in sight to this alarming trend.
A GOOD PROGNOSIS
HEALTH CARE FUNDS HAVEN'T BEEN WINNING ANY POPULARITY contests lately. Only $150 million flowed into the category in 2005, on the heels of a $1.45...
Buying The Future
If you were to suggest to colleagues or clients that the biotechnology sector presents a good opportunity for investment, they might very well respond with...